Literature DB >> 16275852

Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.

Dag Nyholm1, Rasmus Jansson, Thomas Willows, Ingela Nilsson Remahl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16275852     DOI： 10.1212/01.wnl.0000183146.78892.3f

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

Review 1.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

Review 2.  Time to change the blind men and the elephant approach to Parkinson disease?

Authors:  Brad A Racette; Allison W Willis
Journal:  Neurology       Date:  2015-06-12       Impact factor: 9.910

Review 3.  Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.

Authors:  Karin Wirdefeldt; Per Odin; Dag Nyholm
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 4.  Surgical Management of Parkinson's Disease in the Elderly.

Authors:  Paula Azevedo; Camila C Aquino; Alfonso Fasano
Journal:  Mov Disord Clin Pract       Date:  2021-02-27

Review 5.  24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations.

Authors:  Sandeep Thakkar; Victor S C Fung; Aristide Merola; Meredith Rollins; Michael J Soileau; Norbert Kovács
Journal:  CNS Drugs       Date:  2021-02-13       Impact factor: 5.749

6.  Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.

Authors:  Francesc Valldeoriola; María José Catalán; Francisco Escamilla-Sevilla; Eric Freire; Jesús Olivares; Esther Cubo; Diego Santos García; Matilde Calopa; Pablo Martínez-Martín; Juan Carlos Parra; Gloria Arroyo; José Matías Arbelo
Journal:  NPJ Parkinsons Dis       Date:  2021-11-30

7.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 8.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

Review 9.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.

Authors:  Jens Volkmann; Alberto Albanese; Angelo Antonini; K Ray Chaudhuri; Carl E Clarke; Rob M A de Bie; Günther Deuschl; Karla Eggert; Jean-Luc Houeto; Jaime Kulisevsky; Dag Nyholm; Per Odin; Karen Østergaard; Werner Poewe; Pierre Pollak; Jose Martin Rabey; Olivier Rascol; Evzen Ruzicka; Michael Samuel; Hans Speelman; Olof Sydow; Francesc Valldeoriola; Chris van der Linden; Wolfgang Oertel
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

10.  24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease.

Authors:  Belinda Cruse; Hugo Morales-Briceño; Florence C F Chang; Neil Mahant; Ainhi D Ha; Samuel D Kim; Nigel Wolfe; Vu Kwan; David S Tsui; Jane M Griffith; Donna Galea; Victor S C Fung
Journal:  NPJ Parkinsons Dis       Date:  2018-11-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.